Today, we received approvals to initiate the Phase 1 trial of EMP-01, an MDMA derivative, being developed for the treatment of #PTSD Phase 1 is a critical first step in establishing safety & tolerability. We look forward to results expected in H2 2023 bit.ly/3ram1z5

Congrats to our team for receiving approval to initiate the Phase 1 study of EMP-01 for the treatment of #PTSD. We look forward to the results expected later in 2023; a critical milestone in helping to provide relief to the 9.3m people suffering from this debilitating illness.

We're partnering with nature to present a #webinar on 10/6 at 12pm ET discussing the landscape of therapeutic #psychedelics Tune in to learn more about the path forward for advancing these innovative compounds and the future of #mentalhealth bit.ly/3EmrT0d

We are thrilled to announce the first subject dosed in our Phase 1 trial for buccal and IV VLS-01, a form of #DMT for the relief of treatment-resistant depression #TRD. Topline results expected in H1 2023. ir.atai.life/news-releases/…

This #WorldMentalHealthDay, hear from neuroscientist, clinical psychologist, and our scientific advisor Dr. Heather Berlin, and join us in our mission to #healmentalhealth for everyone everywhere.

#hlth2022 has kicked-off! This is the first year that novel mental health treatments using #psychedelics are part of the program. Excited to be part of the @atai_life team introducing this important innovation to the wider HLTH ecosystem.

Congrats to our CEO Florian Brand (and Rihanna) for making FORTUNE’s #40under40 list of influential individuals shaping the world 🎉 We're so proud of you, Florian. Make sure you catch his talk on #mentalhealth at #HLTH2022 @ 4:20pm PST today! fortune.com/40-under-40/20…

I wrote to DEA HQ to support their increased aggregate production quota for #psychedelics. I'm encouraged that the agency is prioritizing access to scheduled substances for clinical research in #mentalhealth.

#ICYMI: The Times and The Sunday Times' Science Editor Ben Spencer wrote a special report on #mentalhealth & #psychedelics “Between [atai and @COMPASS], the two companies have eight compounds in clinical trials, from MDMA [-derivative] and ibogaine to dimethyltryptamine.” thetimes.co.uk/article/psyche…